Long-term responders to trastuzumab monotherapy in first-line HER-2+ advanced breast cancer: characteristics and survival data.

Details

Ressource 1Download: 31500588_BIB_7B45E5A3F16D.pdf (1108.45 [Ko])
State: Public
Version: Final published version
License: CC BY 4.0
Serval ID
serval:BIB_7B45E5A3F16D
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Long-term responders to trastuzumab monotherapy in first-line HER-2+ advanced breast cancer: characteristics and survival data.
Journal
BMC cancer
Author(s)
Schmid S., Klingbiel D., Aebi S., Goldhirsch A., Mamot C., Munzone E., Nolè F., Oehlschlegel C., Pagani O., Pestalozzi B., Rochlitz C., Thürlimann B., von Moos R., Weder P., Zaman K., Ruhstaller T.
ISSN
1471-2407 (Electronic)
ISSN-L
1471-2407
Publication state
Published
Issued date
10/09/2019
Peer-reviewed
Oui
Volume
19
Number
1
Pages
902
Language
english
Notes
Publication types: Clinical Trial, Phase III ; Journal Article
Publication Status: epublish
Abstract
The impact of HER2-targeted therapy alone followed by the addition of chemotherapy at disease progression (PD) versus upfront combination was investigated by the SAKK 22/99 trial. The aim of this exploratory analysis of the SAKK 22/99 trial was to characterize the specific subset of patients deriving long-term benefit from trastuzumab monotherapy alone and to identify potential predictive factors of long-term response.
This is an unplanned post-hoc analysis of patients randomized to Arm A (trastuzumab monotherapy). Patients were divided in two groups: patients with durable clinical benefit from trastuzumab monotherapy and short-term responders without durable clinical benefit from trastuzumab monotherapy Univariate and multivariate analyses of clinical characteristics correlating with response duration was performed.
Eighty six patients were randomized in arm A, 24 patients (28%) were long-term responders and 62 (72%) were short-term responders with a 5y-overall survival (OS) of 54% (95% CI 31-72) and of 18% (95%CI 10-30), respectively. Absence of ER expression, absence of PgR expression and presence of visceral disease emerged as possible negative predictive factors for durable clinical benefit.
Durable clinical benefit can be achieved with trastuzumab monotherapy in a subgroup of HER2-positive patients with advanced disease and it is predictive for longer OS. Further investigations of predictive biomarkers are necessary to better characterize this subgroup of patients and develop further de-escalating strategies.
NCT00004935 ; first posted 27.01.2003, retrospectively registered.
Keywords
Aged, Antineoplastic Agents, Immunological/therapeutic use, Breast Neoplasms/drug therapy, Breast Neoplasms/metabolism, Disease-Free Survival, Female, Humans, Middle Aged, Prognosis, Receptor, ErbB-2, Retrospective Studies, Trastuzumab/therapeutic use, HER-positive breast cancer, Long-term responders, Trastuzumab monotherapy
Pubmed
Web of science
Open Access
Yes
Create date
13/09/2019 11:51
Last modification date
30/04/2021 6:12
Usage data